Allergy Therapeutics (GB:AGY) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Allergy Therapeutics has announced promising interim results from its Phase I/IIa trial of VLP Peanut, a potential new treatment for peanut allergies. The data shows a significant reduction in skin sensitivity among patients and suggests the treatment can effectively boost immune response while reducing allergic reactions. This progress marks a significant step forward in developing a novel therapy for peanut allergy, with plans to continue dose escalation in future trials.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.